Rachel Humphrey serves as Executive at CytomX Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Rachel Humphrey has executed 9 insider transactions totaling $1.2M, demonstrating a bearish approach to their equity position. Their most recent transaction on Mar 26, 2024 involved receiving (via award) 38,741 shares valued at $0.
Rachel Humphrey currently holds 96,805 shares of CytomX Therapeutics, Inc. (CTMX), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Rachel Humphrey has been a net seller of CTMX stock. They have purchased $0 and sold $1.2M worth of shares.
Rachel Humphrey's most recent insider trade was on Mar 26, 2024, when they sold 38,741 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Sep 8, 2020 | BDTX | $0 | Award | 10,000 | $N/A | Discretionary |
| Mar 2, 2018 | CTMX | $484.8K | Sale | 16,160 | $30.00 | Discretionary |
| Mar 2, 2018 | CTMX | $106.8K | Option Exercise | 16,160 | $6.61 | Discretionary |
| Feb 28, 2018 | CTMX | $157.6K | Option Exercise | 23,840 | $6.61 | Discretionary |
| Feb 28, 2018 | CTMX | $715.2K | Sale | 23,840 | $30.00 | Discretionary |
| Dec 15, 2017 | CTMX | $99.9K | Option Exercise | 15,117 | $6.61 | Discretionary |
| Dec 28, 2016 | CTMX | $99.9K | Option Exercise | 15,117 | $6.61 | Discretionary |